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Abstract 
Migraine is a common headache disorder that causes significant disabilities. Non-
selective cyclooxygenase (COX) inhibitors (piroxicam, ketoprofen and ibuprofen) are most 
widely-prescribed NSAIDs treatment of headaches. Celecoxib is another NSAID therapy that has 
been approved in the last several years, with different mechanisms of action. The purpose of the 
study is to follow the renal function and comparisons of nephrotoxicity of different types of 
NSAID based on COX inhibition, in patients with cefalea-migraine that has been treated for a 
long period. 
Besides conventional markers of renal function (serum/urine creatinine determined by 
Jaffe's methods of enzymatic assay for urea in serum), we used nephelometry by β2 
microglobulin (β2M) and photoelectric colorimetry for microalbuminuria in urine, to monitor 
glomerular and tubular functioning. Any history of kidney diseases was exclusion criteria to 
enter the study. 
The results show that the greatest deviations are observed in β2M in terms of its increase 
in all patients treated with piroxicam and ketoprofen, in 91.7% of the patients treated with 
ibuprofen, and in 50% of patients treated with celecoxib. The most frequent decrease was shown 
in creatinine values in urine, in 50% of the patients of piroxicam-treated group, 66.7% of the 
group treated with ketoprofen and ibuprofen, and 75% of the patients treated with celecoxib. 
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Following the levels of specific biomarkers in urine we can recommend constant 
monitoring of renal functions during usage of different groups of NSAIDs and be careful while 
using analgesic-anti-inflammatory drugs. 
 
Keywords: adverse renal effects, non-steroidal anti-inflammatory drugs, migraine 
 
Introduction   
 
Migraine is the most common cause of headache and contributes to severe neurological 
disorder with serious socioeconomic burden. Its prevalence ranges between 12% and 20% in 
different countries worldwide, more common in women than in men. According to Lipton et al. 
(2001), Rozen et al. (1999) and Stewart et al. (1992), 80% of the patients report a family history. 
Despite introducing triptans, a new class of migraine-specific drugs more than a decade ago, with 
superior efficacy, non-steroidal anti-inflammatory drugs (NSAIDs) remains among the most 
commonly used migraine attack therapies, suggested by the European Federation of Neurological 
Societies - EFNS (Evers et al., 2009). Some groups of treatments are available in pharmacies 
without a prescription and are usually much cheaper than triptans, which contributes to their 
abuse among patients suffering from migraine. According to Tulunay et al. (2000) their usage in 
treatment of migraine is followed by their analgesic, anti-inflammatory and antipyretic effects, 
including other pain etiologists, supported by indirect evidence that prostaglandins are involved 
in the pathophysiology of migraines  
According to the results of the studies of Derry et al. (2014), Rothrock et al. (2011) and 
Quiralte et al. (2007), diclofenac has been shown to be one of the world's most widely prescribed 
NSAIDs as an inhibitor - both cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) and 
presenting great efficacy in ranking the therapeutic options for migraine therapy with advantages 
over oral sumatriptan. Conventional NSAIDs are an nonselective inhibitors of both isoforms, 
unlike COX-2-specific NSAIDs, which are also effective in relieving the symptoms of migraine. 
New COX-2 inhibitors (coxibi) are highly effective and more rapidly absorbed by non-selective 
inhibitors, providing benefits in rapid mechanism of action for acute drug therapy and preventing 
the development of central sensitization, which reduces the likelihood of a successful outcome. 
Meloxicam is another selective COX-2 inhibitor that NSAIDs had approved in recent years 
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(Furst et al., 1997). According to Sagar et al. (2011), the efficacy of a new oral liquid formula of 
celecoxib intended for the acute treatment of adults with episodic migraine. 
Based on the selective COX inhibition in accordance to COX-1/COX-2 - IC50 coefficient 
NSAIDs are divided into: 
• Selective COX-1 inhibitors such as aspirin with COX-1/COX-2 coefficient IC50 of 0.01. 
• Non-selective COX inhibitors (the drug equally inactivates the two cyclooxygenase 
isoforms): with COX-1/COX-2 - IC50 coefficient between 0.5 and 3; 
• Relatively selective COX-2 inhibitors - are characterized by a lower inactivation of the 
COX-1 enzyme such as: meloxicam, nimesulide, diclofenac, with COX-1/COX-2 - IC50 
coefficient between 10 and 20; Highly selective COX-2 inhibitors, a celecoxib prototype 
with COX-1/COX-2 - IC50 coefficients between 140 and 250, placebo-controlled COX-2 
only, are known as coxibs and referred to as selective COX-2 inhibitors (Sylejman et al., 
2007; Yzeri Havziu, 2014). 
The main effect of conventional NSAIDs is the nonselective inhibition of both isoforms, 
unlike Coxibs, a class of non-steroidal anti-inflammatory drugs (NSAIDs) that perform selective 
inhibition only COX-2. According to Raz et al. (2002) and Parezela et al. (2001), the paradox is 
that most NSAIDs also block COX-1 and not only COX-2, which means that they block the 
synthesis of all prostaglandis, effecting the normal physiological renal function. Wilam et al. 
(2000) have confirmed that concomitant prostaglandin inhibition in the kidney can reduce renal 
blood flow and glomerular filtration rate (GFR). Thereby, promoting sodium and water retention, 
where renal hypoperfusion may result in acute kidney injury (AKI). This risk is present even 
when COX-2 selective NSAIDs are used. Up to 20% of patients who take nonselective NSAID 
and have more than one of these risk factors may manifest alterations in renal function 
(Raymond et al., 2006). 
Many studies have suggested that COX-2-selective inhibitors cause less renal side 
effects, including decreased glomerular filtration rate (GFR), elevated serum creatinine (CrS) 
and hypertension, comparing to non-selective NSAIDs (Silverstein et al, 2000; Whelton et al., 
2000). On the other hand, other studies did not show significant differences in renal risk between 
COX-2 - selective inhibitors and non-selective NSAIDs (Swan et al., 2000; Whelton et al., 
2000).  
doi:       Original scientific paper 
*Corresponding author email: drite.havziu@unite.edu.mk               6 
According to the study of Weir et al. (2002), based on clinical trials on comparing renal 
changes between non-selective NSAIDs and coxibi, the results indicate only subtle changes in 
renal hemodynamics. They found that the renal effects of celecoxib are similar to non-selective 
NSAIDs. The highest incidence of AKI (Acute kidney injury) is reported during usage od 
Indomethacin in combination with ibuprofen and piroxicam (Griffin et al., 2000). Celecoxib, a 
selective COX-2 inhibitor, has a lower risk of developing AKI, compared to other non--selective 
NSAIDs (Schneider et al., 2006; Winkelmayer et al., 2008). According to Swan et al. (2006), 
diclofenac sodium, compared to meloxicam resulted in a higher degree of nephrotoxicity. So 
they suggested that diclofenac sodium can be replaced with meloxicam. The damaging effects of 
diclofenac sodium and meloxicam on kidney tissue in animals are well documented in the 
literature.  
Many nephrologists report that NSAIDs have been classified into the second group, after 
nephrotoxicity and aminoglycosides as the cause of AKI (Schrier et al., 1984). More recent 
studies have summarized enumerated phases of nephrotoxicity caused by NSAID as following 
conditions: acute renal impairment, chronic renal impairment, interstitial nephritis, and 
subclinical nephrotoxicity. It is clear that all NSAID groups are associated with all forms of renal 
impairment, but however, if detected early, acute syndromes have a good prognosis, However, 
this assumption does not apply to chronic renal impairment (Clive et al., 1984; Ejaz et al., 2004; 
Yzeri Havziu, 2014). 
Traditional laboratory analyzes for the detection of renal impairment, which includes 
creatinine, creatinine clearance, urea, electrolytes, are not only sensitive and specific, but they 
also do not allow early detection of renal impairment. That effects the adequate detection of 
differentiation between the various degrees of AKI and as such cannot be used as a signal for 
stopping therapy with drugs that exhibit strong nephrotoxicity (Liangos et al., 2007). In fact, 
until recently the rise in serum creatinine  (CrS) was widely considered to be the "gold standard" 
for detecting AKI. It is now clear that CrS changes when 50% of renal function is lost. It is 
therefore very important, in addition to these parameters, to follow certain biomarkers, which 
were previously determined in vivo conditions on experimental animals and then used as 
modeling systems for the human organism (Prasad et al., 2005; Yzeri Havziu, 2014). 
Recent literature data suggests the possibility of monitoring the bioindicator early 
detection of nephrotoxicity occurring during NSAIDs (Spasovski et al., 2007; Yzeri Havziu, 
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2014) proteins and albumin that can be of serum or urinary origin are used as biomarkers. 
Excretion of high molecular weight albumin and protein (> 80000) in urine indicates damage to 
glomeruli (Davis et al., 1994), and low molecular weight proteins and albumin: ß2M,  indicates 
changes in the tubules.  
There is relatively little data to compare the nephrototoxicity of different types of 
NSAIDs based on COX inhibition in patients with cephalea-migraines, treated in different 
periods times. The purpose of the study is to compares renal function based on COX inhibition 
and detect early nephrotoxicity using specific bioindicators. 
 
Materials and methods 
 
To accomplish the goal of this study we used urine and venous blood from randomly 
selected patients of Clinical Center-Neurology-Tetovo (Polog Region of R.N.M), with chronic 
headache--migraine, with normal renal function. The study included a total of 48 patients with an 
average age of 42.047±7.41 years, with a range of 35-65 years with mean follow-up of up to 
120±12.6 months treated with different groups of NSAID: non selective COX inhibitors 
(piroxicam, ketoprofen and ibuprofen) and selective COX-2 inhibitors (celecoxib). The dose, 
treatment period, migraine episodes and drug usage frequency are displayed in Table 1. 
 
Table 1 
 
Patients included in the examination were informed about the method of implementation 
and the purpose of the research before giving their written consent. They were also asked not to 
use any other medicines before taking the examinations. Patients with prior renal disease were 
excluded from the study. The examination was conducted according to the designed protocol, 
respecting the ethical principles of the Helsinki Declaration on Medical Research on People and 
Licenses from the Ethic Committee of the Faculty of Medical Sciences at the University "Goce 
Delcev" – Stip (WMA, 2000). The results represent the average value of the three measurements, 
made under identical conditions. In purpose of analysis sample was used 5 mL of blood, 
collected in special tubes, without anticoagulants. All materials for analysis are measured in the 
laboratories of Clinical Hospital in Tetovo. 
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To determine of creatinine and specific biomarkers (β2M and microalbuminuria), the first 
morning urine was used. The samples were processed according to the protocol described by 
Yzeri Havziu et al. (2016) and subsequently used for further biochemical characterization. 
For testing the creatinine serum/urine, we used the Jaffe method - during the reaction of 
the creatinine with the basic reagents (Flex reagent cartridge), a complex of red color is formed, 
which is followed by measuring the change of absorbance at a time interval of 510 nm 
(Dimension Rxl) (Yzeri Havziu et al., 2017). 
Urea serum, the enzymatic-urea hydrolysis under the influence of the urease enzyme, the 
formed ammonia (NH3) reacts with the catalytic effect of the GLDH (Flex Reagent Cartridge), α-
KG (Flex Reagent Cartridge) and NADH (Flex Reagent Cartridge). As a result of the reaction, 
glutanamic acid and NAD are formed. The decrease in absorbance due to the reduced NADH 
oxidation is proportional to the release of the urea NH3, measured at a value of 340 and 383 nm 
(Dimension Rxl) (Yzeri Havziu, et al., 2017).  
Serum electrolytes - Ion Selective Electrodes (ISE) - determine the difference in the 
electrochemical potential between the glass or liquid membrane electrode (Flex Reagent 
Cartridges) and the reference electrode (Flex Reagent Cartridges) that is proportional to the 
concentration of electrolytes in the serum. 
For the determination of urinary albumin, microalbuminuria, we used visual Reading 
urine tape test in Combilyzer 13 - a test is based on the "protein error" principle of the indicator, 
which is caused by the presence of albumin. Sulfanephthalein has a high sensitivity to albumin. 
The color fields correspond to following values: 10, 30, 80 and 150 mg/L urinary albumin. 
For β2M determination imunonephelometry by BN II/BN ProSpecR System was used. 
 
Statistical data processing  
 
Statistical data processing was performed in SPSS for Windows 23.0 statistical software. 
Shapiro-Wilks tests, as well as skewness and kurtosis measures were used to test the 
normality of the data distribution.  
Nonparametric and parametric tests for independent samples (H Kruskal-Wallis test) and 
post - hoc (Mann-Whitney test), were used to compare the analyzed groups. The data of interest 
are shown in tables and graphs. P values <0.05 were considered statistically significant 
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Results and discussion 
 
Results of comparison of mean and median values of the analyzed parameters 
(biochemical parameters and specific bioindicators) of 48 patients treated with piroxicam, 
ketoprofen, ibuprofen and celecoxib are shown in Tables 2 and 3. 
 
Table 2 
 
Table 3 
 
From the results presented in Table 2 and 3 it is observed that patients treated long-term 
with piroxicam, ketoprofen, ibuprofen and celecoxib, who had shown migraine episodes lasting 
less than 15 days per month, had significantly different serum urea (BUN), sodium in serum, 
microalbuminuria and β2M levels. Significant difference was observed for patients treated with 
piroxicam, ketoprofen, ibuprofen and celecoxib with respect to serum urea concentrations at 
p=0.0001. This overall significance was due to significantly higher urea values in the group 
treated with ketoprofen compared to the group treated with ibuprofen (median 5.55 vs 4.15, 
p=0.045), and significantly higher values in the group treated with celecoxib compared to the 
treated group of piroxicam and ibuprofen (median 6.4 vs 4.4, p=0.003; 6.4 vs 4.15, p=0.0004).  
Post-hoc analysis of the inter-group differences between piroxicam, ketoprofen, 
ibuprofen and celecoxib comparing to the serum sodium concentrations showed that this overall 
significance was due to a significantly higher serum sodium level in patients treated with 
piroxicam compared to patients receiving celecoxib (median 140 vs 137, p=0.033). The results 
were of great clinical relevance because they indicate that NSAIDs, as cyclooxygenase inhibitors 
(non-selective COX-1 inhibitor and selective COX-2 inhibitor) influence the increase in 
degradation products (serum urea, creatinine in serum and urine) as well as changes in tubular 
electrolyte reabsorption. The results correspond to those of Kim and Clive (2007) and their 
associates who followed patients with an increased predisposition to nephrotoxicity when treated 
with non-selective NSAID and selective COX-2 inhibitors - celecoxib. Both groups showed 
changes in electrolyte status, with marked hyponatraemia and hyperkalemia. On the other hand, 
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Hegazy et al. (2011) following serum creatinine, clearance creatinine, and serum electrolytes, 
concluded that patients treated with ibuprofen had significantly higher serum creatinine values 
compared to patients treated with celecoxib. In both patient groups, insignificant changes in 
serum electrolyte levels were observed. 
In fact, while until recently elevated serum creatinine was largely considered the "gold 
standard" for detecting AKI. Nowadays, it is clear that serum creatinine changes when 50% of 
renal function is lost. According the results of the study conducted by Mahrukh et al. (2017), the 
blood urea (BUN) levels can be falsely elevated in subjects with protein diet, tissue disorders, 
gastrointestinal bleeding, total parenteral nutrition and dehydrated individuals. 
It is therefore very important, in addition to these parameters, to follow specific 
biomarkers for early identification of renal impairment such as low molecular protein 
(microalbuminuria and β2M). 
Urinary albumin excretion was significantly different in the groups treated with 
piroxicam, ketoprofen, ibuprofen, and celecoxib (p=0.017). Intergroup trials and comparisons 
have shown that treatment with ketoprofen significantly increases microalbuminuria (marker for 
early detection of glomerular damage) compared to treatment with celecoxib  (median 30 vs 10, 
p=0.048). At p=0.0003, a significant overall difference between the four groups of patients and 
β2M (markers for early detection of proximal tubular damage) values was confirmed. Values of 
this parameter were significantly lower in patients treated with celecoxib compared to patients 
treated with piroxicam (p=0.013) and ketoprofen (p=0.003). Mean β2M values in patients treated 
with piroxicam, ketoprofen, ibuprofen and celecoxib were 0.206 vs 0.201. The results are of 
great clinical relevance because they indicate that in patients with cephalea-migraines, changes 
in glomeruli and proximal tubules have been identified, whereas in patients with celecoxib they 
have been found to be significantly lower in values or smaller changes in renal function, is 
believed to be due to shorter treatment time for patients with Celecoxib 200 mg over a 12-month 
period compared to other NSAID groups treated over a longer period of 5 to 10 years, the 
sensitivity of biomarkers is also confirmed. These results correspond with the claims of Pedersen 
et al. (1995), that biomarker microalbuminuria is a more sensitive indicator for the identification 
of renal dysfunction and should be used as a useful tool for the management of non-clinical 
patients. According to Swan et al. (2000), relatively selective COX-2 inhibitors are more 
renoprotective than COX-1 inhibitors, consequently, there is evidence of a higher incidence of 
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acute kidney injury (AKI) in patients treated with COX-1 inhibitors (indomethacin, ibuprofen 
and piroxicam) (Griffin et a.l, 2003; Silverstein et al., 2000). To confirm the sensitivity of 
specific biomarkers the comparison of piroxicam, ketoprofen, ibuprofen and celecoxib with 
respect to the analyzed parameters are presented in Table 4. 
  
Table 4 
 
Table 4 is showing the distribution of the frequency of increased or reduced values of the 
parameters analyzed in groups piroxicam, ketoprofen, ibuprofen and celecoxib. The results show 
that the greatest deviations were observed in β2M in terms of its increase in all patients treated 
with piroxicam and ketoprofen, in 91.7% of the patients treated with ibuprofen, and in 50% of 
the patients treated with celecoxib. Tested difference of the distribution of patients with normal 
values and deviations from the reference values among the three drug groups was statistically 
significant for chlorides (p=0.016), microalbuminuria (p=0.029) and β2M (p=0.002). The most 
frequent decrease was in creatinine values in the urine, i.e. 50% of patients in the group treated 
with piroxicam, 66.7%  of the group treated with ketoprofen and ibuprofen, and 75% of patients 
treated with celecoxib had decreased creatinine in the urine, which from a clinical biochemical 
point of view have no clinical significance. 
Based on the data obtained for microalbuminuria and β2M in patients with chronic 
headache-migraine, the identified changes in the tubules. From a biochemical point of view, this 
suggests that cyclooxygenase inhibitors have a significant effect on changes in epithelial cels of 
proximal tubules which is directly related to the increase in urinary excretion of low molecular 
protein β2M (as early marker for identifieating tubular disfunctionin) and catabolism in the 
proximal tubules. Based on monitoring of microalbuminuria (as a marker for early identification 
of renal impairment at the glomerular level), changes in glomeruli have been detected, which 
once again confirm the sensitivity of specific biomarkers.  
On the basis of monitoring the frequency distribution of increased or decreased values of 
the analyzed parameters according to the nephrological protocol serum urea (BUN), serum 
creatinine (CrS), urinary creatinine (CrU) in the groups, an increase was observed only in the 
values of urea serum (BUN) but it does not have particular clinical importance since (Mahrukh et 
al., 2017). 
doi:       Original scientific paper 
*Corresponding author email: drite.havziu@unite.edu.mk               12 
 
Conclusion 
 
Sensitivity of specific bioindicators to detect early stage nephrotoxicity at glomerular level 
– microalbuminuria, as well as at tubular level - and β2M has been demonstrated in the treatment 
of patients with cephalea with non-selective COX inhibitors (piroxicam, ketoprofen and 
ibuprofen) and selective COX-2 inhibitors (celecoxib). Based on the results, we confirm the 
renoprotection of celecoxib. Individualized and rational use of NSAIDs is recommended, due to 
the danger of increasing the potential for nephrotoxicity over the duration of therapy as well as 
constant monitoring of renal function in patients. 
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Резиме 
 
Споредба на негативни бубрежни ефекти на различни видови на НСАИЛ врз основа 
на инхибиција на COX кај пациенти со главоболки. 
 
Дрита Узеири Хавзиу1, Билјана Ѓорѓеска2, Висар Мифтари3, Едита Алили Идризи1, 
Ѓулај Алија1, Арлинда Хаџиу Заими1 
 
1Факултет за медицински науки, Државен универзитет во Тетово, ул. Илинден бб 1200, 
1220 Тетово, Република Северна Македонија 
2Медицински факултет, Универзитет „Гоце Делчев”, ул. Крсте Мисирков, 2000 Штип, 
Република Северна Македонија 
3Клиника за неврологија, Клиничка болница, ул. 29 Ноември, 1220 Тетово,  
Република Северна Македонија 
 
Клучни зборови: несакани бубрежни ефекти, нестероидни антиинфламаторни лекови, 
мигрена 
 
Мигрената претставува вообичаенa главоболка, која предизвикува значајни 
пореметувања. Неселективните инхибитори на циклооксигеназата (СОХ): пироксикам, 
кетопрофен и ибупрофен се најчесто препишуваните нестероиди антиинфламаторни 
лекови (НСАИЛ) наменети за третман на главоболка. Целекоксиб е уште еден НСАИЛ 
којшто е одобрен во последните неколку години, кој се карактеризира со различни 
механизми на делување. Целта на оваа студија е да се следи реналната функција и да се 
споредат нефротоксичните делувања на различните видови НСАИЛ чие што дејство се 
заснова на инхибиција на COX, кај пациетни со цефалеа-мигрена кои што се третирани 
подолг период.   
Покрај конвенционалните маркери на реналната функција (креатинин во 
серум/урина, определен според Jaffe-овата метода и уреа во серум, oпределена со 
ензимска метода), со цел мониторирање на гломеруларните и тубуларните функции, 
користевме нефелометрија за определување на β2 Microglobulin (β2M) и фотоелектрична 
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колоримтерија за определување на микроалбуминуријата во урината. Било каква историја 
на заболување на бубрезите беше критериум за исклучување на пациентите од оваа 
студија. 
Резултатите покажуваат дека постои голем пораст на нивоата на β2М  кај сите 
пациенти кои беа под терапија со пироксикам и кетопрофен, кај 91,7% од пациентите под 
терапија со ибупрофен, и кај 50% од пациентите под терапија со целекоксиб. Најчестото 
зголемување беше забележано кaj вредностите на креатининот во урината, кај 50% од 
пацентите третирани со пироксикам, 66,7 % од пациентите третирани со кетопрофен и 
ибупрофен, и 75% од пациентите третирани со целекоксиб.  
Врз основа на добиените резултати за нивоата на специфичните биомаркери во 
урината, ние препорачуваме постојано следење на реналните фунции при користење на 
различни групи НСАИЛ и внимателност при користење аналгетици и антиинфламаторни  
лекови. 
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Table 1. Drugs, Dose, treatment period, migraine episodes and drug usage frequency 
 
Drugs N Dose 
Mg 
 
(per day) 
Period of 
Treatement  
 
(per year) 
Migraine 
Episodes 
 
(days in month) 
Drug Usage 
Frequency 
 
(days in month) 
Piroxicam  12 20 >5 to10 <15 <15 
Ketoprofen 12 100 >5 to10 <15 <15 
Ibuprofen  12 600 5 <15 <15 
Celecoxib 12 200 1 <15 <15 
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Table 2. Comparison of the mean and median values of the analyzed parameters (BUN, CrS, 
CrU, NaS) of Piroxicam, Ketoprofen, Ibuprofen and Celecoxib. 
 
Biochemical 
Parameters 
median 
(25-75 percentiles) 
p-level 
 intergroup differences 
 Кetoprofen Ibuprofen Celecoxib 
1BUN 4.4 (3.75-4.75) H=20.79 
p=0.0001 sig 
Piroxicam ns ns 0.0030 
5.55 (4.7-7.05) Кetoprofen  0.0450 ns 
4.15 (4.11-4.7) Ibuprofen   0.0004 
6.4 (6.3-6.6) Celecoxib    
1CrS 65.5 (59.5-78.5) H=6.42 
p=0.0900 ns 
Piroxicam    
63 (50.5-71) Кetoprofen    
 68 (61.5-83)  Ibuprofen    
 82 (74.5-82.5)  Celecoxib    
1CrU 13.25 (8.8-17.7) H=3.88 
p=0.2700 ns 
Piroxicam    
8.8 (6.6-15.5) Кetoprofen    
8.8 (8.8-17.7)  Ibuprofen    
 4.4 (4.4-13.25)  Celecoxib    
1NaS 
 
140 (138.5-140.5) H=9.38 
p=0.02500 sig 
 
Piroxicam ns ns 0.0330 
139.5 (137.5-140.5) Кetoprofen  ns ns 
 138 (138-140.5) Ibuprofen   ns 
 137 (137-137.5) Celecoxib    
 
*H (Kruskal-Wallis test)   
* post - hoc (Mann-Whitney test)  
* BUN - serum urea, CrS - serum creatinine, CrU - urinary creatinine, NaS – sodium in serum 
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Table 3. Comparison of the mean and median values of the analyzed parameters (KS, ClS, MA 
and β2M) of Piroxicam, Ketoprofen, Ibuprofen and Celecoxib. 
Biochemical 
Parameters 
median  
(25-75 percentiles) 
p-level 
Group 2/3/8/9 
Groups 
 Кetoprofen Ibuprofen Celecoxib 
KS 4.4 (4.1-4.55) H=3.59 
p=0.3100 ns 
Piroxicam    
4.55 (4.15-5.1) Кetoprofen    
4.2 (4.2-4.65) Ibuprofen    
4.2 (4.2-4.35) Celecoxib    
ClS 100.5 (98.5-101.5) H=3.41 
p=0.3300 ns 
Piroxicam    
99 (98-100) Кetoprofen    
 97.5 (97-100.5)  Ibuprofen    
 99 (99-100)  Celecoxib    
MA 20 (10-30) H=10.12 
p=0.0170 sig 
Piroxicam ns ns ns 
30 (20-30) Кetoprofen  ns 0.0480 sig 
10 (10-30)  Ibuprofen   ns 
 10 (10-10)  Celecoxib    
β2 M 0.206 (0.206-0.209) H=18.53 
p=0.0003 ns 
Piroxicam ns ns 0.0130 sig 
0.206 (0.206-0.213) Кetoprofen  ns 0.0030 sig 
0.206 (0.203-0.206) Ibuprofen   ns 
 0.201 (0.186-0.206) Celecoxib    
 
*H (Kruskal-Wallis test)   
* post - hoc (Mann-Whitney test)  
ClS -chlorides in serum, M A- microalbuminuria, β2M - β2 microglobulin. 
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Table 4. Comparison-Piroxicam, Ketoprofen, Ibuprofen and Celecoxib, with respect to the 
parameters analyzed (normal values and values deviating from the reference). 
Biochemical 
parameters 
  
Values 
Group 
Ref. 
value Unites N 
Piroxicam 
N=12 
Кetoprofen 
N=12 
Ibuprofen 
N=12 
Celecoxib 
N=12 
BUN 2.5-6.4 mmol/L Increased 10 2 (16.67) 3 (25) 0 5 (41.67) 
p-level   b0.097 ns      
 
CrS 
 
49-90 
 
μmol/L 
 
Reduced 
 
4 
 
0 
 
3 (25) 
 
0 
 
1 (8.33) 
p-level   b0.173 ns      
 
CrU 
 
13.3-22.1 
 
mmol/L 
 
Reduced 
 
31 
 
6 (50) 
 
8 (66.67) 
 
8(66.67) 
 
9 (75) 
p-level   b0.716 ns      
 
NaS 
 
136-143 
 
mmol/L 
 
Reduced 
 
2 
 
0 
 
0 
 
1 (8.33) 
 
1 (8.33) 
ClS 3.5-5.1 mmol/L Reduced 9 2 (16.67) 0 6 (50) 1 (8.33) 
p-level   b0.016 sig      
 
МА 
 
<20 
 
mg/L 
 
Increased 
 
21 
 
6 (50) 
 
9 (75) 
 
4 (33.33) 
 
2 (16.67) 
p-level   a0.029 ns      
 
β2 M 
 
<0.2 
 
mg/L 
 
Increased 
 
41 
 
12 (100) 
 
12 (100) 
 
11 (91.67) 
 
6 (50) 
p-level   b0.002 sig      
  
* BUN - serum urea, CrS - serum creatinine, CrU - urinary creatinine, NaS - sodium in serum, ClS -
chlorides in serum, MA - microalbuminuria, β2M - β2 microglobulin. 
 
 
 
 
